2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P4893
    (Gln22,Asn23)-Amyloid β-Protein (1-40) 374796-75-5 98%
    (Gln22,Asn23)-Amyloid β-Protein (1-40) is a peptide. (Gln22,Asn23)-Amyloid β-Protein (1-40) can be used for the research of Cerebral Amyloid Angiopathy Mutations.
    (Gln22,Asn23)-Amyloid β-Protein (1-40)
  • HY-P4898
    Anthopleurin-A 98%
    Anthopleurin-A is a soidum channel toxin. Anthopleurin-A is selective for cardiac channels and has cardiotonic effect. Anthopleurin-A can be isolated from the sea anemone.
    Anthopleurin-A
  • HY-P4908
    S-(1,2-Dicarboxyethyl)glutathione 1115-52-2 98%
    S-(1,2-Dicarboxyethyl)glutathione is a peptide that inhibits blood coagulation and platelet aggregation.
    S-(1,2-Dicarboxyethyl)glutathione
  • HY-P4911
    SDF-1α (human) 1268129-65-2 98%
    SDF-1α (human) is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) can be used in cardiovascular disease research.
    SDF-1α (human)
  • HY-P4994
    Val9-Oxytocin 1021701-88-1 98%
    Val9-Oxytocin is a full antagonist of vasopressin (V1a) receptor. Val9-Oxytocin is an analog of Oxytocin (HY-17571A) in which changing Gly9 to Val9.
    Val9-Oxytocin
  • HY-P5007
    Copeptin (human) 78362-34-2 98%
    Copeptin (human) is a diagnostic and prognostic biomarker for cardiovascular disease (CVD). Copeptin (human) is also the carboxyl terminus of the arginine vasopressin (AVP) precursor peptide. Copeptin (human) can be used in the study of cardiovascular disease.
    Copeptin (human)
  • HY-P5010
    (D-Arg8)-Inotocin 745816-74-4 98%
    (D-Arg8)-Inotocin is a potent, selective and competitive antagonist of vasopressin receptor (V1aR), with a Ki of 1.3 nM. (D-Arg8)-Inotocin shows more than 3000-fold selectivity for the human V1aR over the other three subtypes, OTR, V1bR and V2R.
    (D-Arg8)-Inotocin
  • HY-P5027
    Cbz-Lys-Arg-pNA 108318-37-2 98%
    Cbz-Lys-Arg-pNA is a peptide substrate containing pNA as the chromogenic group. Cbz-Lys-Arg-pNA is widely used in enzymatic analysis, including thrombin, plasmin, factor Xa and Kallikrein.
    Cbz-Lys-Arg-pNA
  • HY-P5121
    γ-Fibrinogen 377-395 957792-67-5 98%
    γ-Fibrinogen377-395 is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation.
    γ-Fibrinogen 377-395
  • HY-P5130
    Big endothelin-1 (rat 1-39) 98%
    Big endothelin-1 (rat 1-39) is a 39-residues peptide. Big endothelin-1 (rat 1-39) induces diuretic and natriuretic response in conscious Sprague-Dawley rats. Big endothelin-1 (rat 1-39) raises blood pressure in mice.
    Big endothelin-1 (rat 1-39)
  • HY-P5142
    ω-Hexatoxin-Hv1a 193981-10-1 98%
    ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a blocks L-type voltage-dependent Ca2+ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons.
    ω-Hexatoxin-Hv1a
  • HY-P5345
    KLA peptide 184240-26-4 98%
    KLA peptide is a naturally occurring Antibiotic peptide that is nontoxic outside of cells but is toxic when it enters into the interior of targeted cells. KLA peptide can induce cell Apoptosis by disrupting mitochondrial membranes and activating Caspase. MG1-KLA, formed by the coupling of KLA peptide with MG1, can selectively induce apoptosis in pro-inflammatory microglia. KLA peptide can be used for the research of liver fibrosis. KLA peptide can be used for the research of neonatal hypoxic-ischemic encephalopathy.
    KLA peptide
  • HY-P5764
    TRAP-14 amide 141923-36-6 98%
    TRAP-14 amide, a proteinase activated receptor (PAR)-activating peptide, is a PAR agonist with an EC50 of 24 μM. TRAP-14 amide significantly induces platelet aggregation through ADP- and MMP-2-dependent pathways with Aspirin (HY-14654)-insensitivity. TRAP-14 amide also effectively increases glycoprotein (GP) Ib and GPIIb/IIIa surface expression and ADP release.
    TRAP-14 amide
  • HY-P5769
    Endothelin (16-21) 121377-67-1 98%
    Endothelin (16-21) is a selective ETB receptor agonist (EC50=228 nM in guinea-pig bronchus). Endothelin (16-21) can induce smooth muscle contraction. Endothelin (16-21) is promising for research of respiratory (e.g., asthma) and cardiovascular (e.g., hypertension) diseases.
    Endothelin (16-21)
  • HY-P5774
    Leu-Valorphin-Arg 135861-77-7
    Leu-Valorphin-Arg (LVV-hemorphin-6), an opioid active peptide, is an angiotensin converting enzyme (ACE) inhibitor. Leu-Valorphin-Arg can be used for hypertension research.
    Leu-Valorphin-Arg
  • HY-P5875
    P4pal10 1021346-05-3 98%
    P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models.
    P4pal10
  • HY-P5889
    Thrombin receptor peptide ligand 287964-20-9 98%
    Thrombin receptor peptide ligand is a thrombin receptor antagonist peptide that can be used as an antithrombotic agent.
    Thrombin receptor peptide ligand
  • HY-P5891
    TAT-SAMβA 98%
    TAT-SAMβA is the peptide consist of RNAENFDRF (SAMβA; HY-P3429) conjugated to the cell penetrating TAT protein-derived peptide TAT47–57. TAT-SAMβA is a selective antagonist of Mfn1-βIIPKC association. TAT-SAMβA protects mouse embryonic fibroblast cells (MEFs) against oxidative stress-induced cytotoxicity.
    TAT-SAMβA
  • HY-P5908
    DEALA-Hyp-YIPD 98%
    DEALA-Hyp-YIPD is an HIF-1α peptide that inhibits VHL/HIF-1α interaction with an IC50 of 0.91 μM and a Kd of 180 nM.
    DEALA-Hyp-YIPD
  • HY-P5913
    [Tyr6]-Angiotensin II 52634-95-4 98%
    [Tyr6]-Angiotensin II is a peptide fragment , and can bind to the angiotensin converting enzyme 2 .
    [Tyr6]-Angiotensin II
Cat. No. Product Name / Synonyms Application Reactivity